Latest Conference Articles

Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.

At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.

Addition of ponatinib led to a higher rate of MRD-negative complete remission vs imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Further investigation into the outcomes of adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia when treated with pediatric-inspired regimens are warranted.

Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/

Adaptation of improved methods of MRD detection are needed to better define this population at risk.

Exploration of aging biomarkers such as senescence-associated secretory phenotype and epigenetic clocks can inform appropriate patient and treatment selection in the future.

The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.

The use of bispecific antibodies has the potential to revolutionize the management of FL.

Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.

Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.

Rami Komrokji, MD, discusses the different systems of classifying myelodysplastic syndrome.

Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.

In the phase 2 KEYNOTE-942 trial, the 18-month distant metastasis-free survival rate was 91.8% with mRNA-4157 plus pembrolizumab vs 76.8% with pembrolizumab alone.

Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.

The use of polatuzumab vedotin in place of vincristine in R-mini-CHOP may lead to an increase in gastrointestinal adverse events in frail patients with diffuse large B-cell lymphoma.

Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.

In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.

OMS906, a MASP-3 inhibitor, demonstrated clinical efficacy in a proof-of-concept study for patients with paroxysmal nocturnal hemoglobinuria, according to an interim analysis presented at the 2023 EHA Congress.

A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.

The KMT2A inhibitor appeared safe and led to clinical activity in the treatment of patients with NPM1-mutated, relapsed/refractory acute myeloid leukemia, according to the phase 1 KOMET-001 trial.

After positive results from the phase 1/2 KRT-232-109 study, the phase 3 BOREAS-2 study will further evaluate the combination of navtemadlin and ruxolitinib in patients with myelofibrosis.

Teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, says María-Victoria Mateos, MD, PhD.

Post-hoc analysis results showed a reduction in spleen volume of 35% with ruxolitinib in patients with myelofibrosis.

With BMS-986158 plus ruxolitinib or fedratinib treatment in patients with myelofibrosis, reduction in splenic volume was reported among all patients in part 1A and became more robust at week 24.

Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Recent studies reported a potential reduction in stem cell yields in patients who were exposed to daratumumab prior to stem cell mobilization.

Interim findings from the phase 2 EMN19 study coupled with the phase 2 LYRA study findings suggest DaraVCD is another option for multiple myeloma with extramedullary disease.